Pipeline of small molecule therapeutics
InMed Pharmaceuticals (NASDAQ: INM) is a clinical-stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications.
Targeting CB1 and CB2 pathways
InMed has initiated three pharmaceutical programs – including preclinical programs in Alzheimer’s disease and age-related macular degeneration, as well as a completed Phase 2 clinical trial for the treatment of epidermolysis bullosa.
InMed’s small molecule compounds are demonstrating promising effects with potentially multiple mechanisms.
INM-901 demonstrates a multi-factorial approach to treating Alzheimer’s disease
INM-901 demonstrates multiple pharmacological effects in preclinical studies including neuroprotective effects, an ability to extend the length of neurites which is important for brain cell-to-cell communication, as well as a reduction in neuroinflammation. These preclinical studies were conducted in well-characterized study models of Alzheimer’s disease.
A library of analogs that can be selectively modified
Unlike natural cannabinoids isolated from the plant which are not patentable, our proprietary cannabinoid analogs are patentable and are recognized as new chemical entities (NCEs). These analogs are expected to offer similar or improved therapeutic effects compared to their parent (naturally occurring) cannabinoid with modifications that may make them preferred candidates to treat specific diseases. We are screening these analogs for their therapeutic properties and pharmaceutical development.
Bringing you highly pure, premium bioidentical rare cannabinoids
InMed’s subsidiary, BayMedica, is producing a portfolio of premium rare cannabinoids as raw ingredients for your health and wellness products. We have engineered bioidentical cannabinoids with high purity and consistency, and free of THC. We currently manufacture the rare, minor cannabinoids cannabichromene (CBC), tetrahydrocannabivarin (d9-THCV), cannabidivarin (CBDV) and cannabicitran (CBTC) which are available for B2B purchase.
Experienced team with a successful track record
Together, InMed and BayMedica bring extensive know-how in pharmaceutical research and development and manufacturing. We’ve combined our complementary expertise to become a leading pharmaceutical R&D company and manufacturer of small molecule therapeutics targeting CB1/CB2 receptors.
